PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “SEER Program”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,243 records · Page 69Linked to original sources

Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection.

OBJECTIVE: To compare surgeon and hospital procedure volume as predictors of outcomes for patients with rectal cancer. SUMMARY BACKGROUND DATA: Although a "volume-outcome" relationship exists for several major cancer operations, the impact of procedure volume on outcomes following rectal cancer surgery remains uncertain, and it has not been determined whether hospital or surgeon volume is a more important predictor of outcomes. METHODS: A retrospective population-based cohort study utilizing the Surveillance, Epidemiology and End Results (SEER)-Medicare linked database identified 2,815 rectal cancer patients aged 65 and older who had surgery for a primary tumor diagnosed in 1992-1996 in a SEER area. Hospital- and surgeon-specific procedure volume was ascertained based on the number of claims submitted over the 5-year study period. Outcome measures were mortality at 30 days and 2 years, overall survival, and the rate of abdominoperineal resections. Age, sex, race, comorbid illness, cancer stage, and socioeconomic status were used to adjust for differences in case mix. RESULTS: Neither hospital- nor surgeon-specific procedure volume was significantly associated with 30-day postoperative mortality or rates of rectal sphincter-sparing operations. Although an association between hospital volume and mortality at 2 years was evident, this finding was no longer significant once surgeon-specific volume was controlled for. In contrast, surgeon-specific volume was associated with 2-year mortality and remained an important predictor even after adjustment for hospital volume. Surgeon volume was also better than hospital procedure volume at predicting long-term survival. CONCLUSIONS: Surgeon-specific experience as measured by procedure volume can have a significant impact on survival for patients with rectal cancer.

Aged↗

Breast cancer incidence in Asian migrants to the United States and their descendants.

We studied breast cancer incidence during the period 1973-1986 in Asian residents of three U.S. geographic areas. The rate in Asian-American women born in China or Japan and in their U.S.-born counterparts was about 50% and 75% that of U.S.-born whites, respectively, and was approximately twice the rate of women residing in Asia. Breast cancer incidence was nearly identical in U.S.- and foreign-born Filipino-Americans, but it was 40% that of U.S.-born whites.

Adult↗

Biased comparisons of lung cancer survival across geographic areas: effects of stage bias.

This report illustrates bias that may affect comparative analyses of cancer survival across geographic areas and describes how it limits the conclusions that can be drawn from such data. Despite the application of a standardized procedure for assigning tumor stage, patients from different areas who are assigned the same stage category may not be homogeneous with respect to extent of disease, if staging is accomplished more aggressively in one group than in another. Stage-specific comparisons of survival may be biased as a result. Cancer sites for which a large majority of patients are treated surgically may be less susceptible to stage bias.

Aged↗

Occurrence of breast cancer in relation to recreational exercise in women age 50-64 years.

To investigate the relation between recreational physical activity and breast cancer, we conducted an analysis of a population-based case-control study of women age 50-64 years in western Washington State. The study included 537 patients with breast cancer diagnosed during 1988-1990 and 492 randomly selected population control women. Detailed information on recreational exercise habits and other risk factors for breast cancer was ascertained by structured in-person interviews. A similar proportion of cases and controls reported exercise in the 2 years before the referent date (about 50%), or during ages 12-21 years (about 40%). Compared with women who reported no exercise, there was a slightly decreased risk of breast cancer in women who exercised more than 1.5 hours per week in the 2 years before diagnosis (cases) or referent date (controls) [odds ratio (OR) = 0.7; 95% confidence interval (CI) = 0.4-1.1], or who engaged in at least some high-intensity exercise (OR = 0.7;95% CI = 0.4-1.1), but there was no clear decline in risk at the highest categories of duration or intensity. There was no association between any intensity exercise at ages 12-21 years and risk of breast cancer. These results indicate a weak negative association between physical activity and risk of breast cancer in middle-aged women.

Breast Neoplasms↗

Induced abortion in relation to breast cancer among parous women: a birth certificate registry study.

We wished to assess the relation of induced abortion to the subsequent incidence of breast cancer among parous women, using a design that would prevent the possibility of differentially complete reporting of abortion history by women with breast cancer and controls. Our study was conducted within a cohort of women who gave birth to a child during 1984-1994 while residing in 13 counties of western Washington. Cases were women from the cohort diagnosed with breast cancer between 1984 and 1994. From the remaining cohort members, five controls were matched to each woman with breast cancer by year of index birth (ie, the last child born before breast cancer diagnosis) and by age at delivery. We categorized 463 cases and 2,201 controls according to history of induced abortion as recorded on the index birth certificate. The risk of breast cancer was not found to be associated with a prior induced abortion (estimated relative risk (RR) = 0.9, 95% confidence interval (CI) 0.7-1.2). These results suggest that an induced abortion, if followed at some later time by pregnancy and childbirth, does not increase a woman's risk of breast cancer.

Abortion, Induced↗

Association of esophageal adenocarcinoma with other subsequent primary cancers.

PURPOSE: Esophageal adenocarcinoma shares risk factors such as obesity and smoking with other common cancers. The association of esophageal adenocarcinoma with other primary cancers has not been systematically evaluated. The authors used the Surveillance, Epidemiology and End-Results database of the National Cancer Institute to explore the association of esophageal adenocarcinoma with other primary cancers. PATIENTS AND METHODS: All adult patients with esophageal cancers, both adenocarcinoma and squamous cell carcinoma diagnosed between 1973 and 2001, were identified from the Surveillance, Epidemiology, and End-Results database, and standardized incidence rates were calculated for all subsequent primary cancers in these patients. The analysis was reversed to estimate the standardized incidence rate for subsequent primary esophageal cancer after a first primary cancer. RESULTS: In comparison with a standard population, patients with esophageal adenocarcinoma were at higher risk for the development of another subsequent cancer, specifically, cancers of the oral cavity and pharynx, lung and bronchus, and kidney and renal pelvis, and adenocarcinoma of the colon/rectum and pancreas. With squamous cell esophageal cancer, there was an association with tobacco-related cancers such as those of the oral cavity and pharynx, the lung and bronchus, and the breast. There was either no association or even a negative association of esophageal adenocarcinoma with other obesity-related cancers such as breast, uterine, and prostate cancers. CONCLUSIONS: Patients with esophageal adenocarcinoma and squamous cell carcinoma are at increased risk for the development of specific second primary cancers that share smoking as a common risk factor. Esophageal adenocarcinoma does not have a strong association with obesity-related cancers with respect to the relative risk for the development of subsequent primary cancers.

Adenocarcinoma↗

Microsatellite alterations in african americans with head and neck cancer.

OBJECTIVE: To determine the genetic differences between African Americans (AA) and Non-African Americans (NAA) with head and neck squamous cell carcinoma (HNSCC). METHODS: DNA was obtained from tumor tissues and peripheral blood from 18 AA and 19 NAA patients with HNSCC. Microsatellite analysis using a fluorescent technique was performed on chromosomal arms 1p, 3p, 4q, 9p, 13q, and 17p. Statistical analyses were performed on the molecular and clinical outcome data. RESULTS: Based on the Surveillance, Epidemiologic, and End Result (SEER) data from southeast Michigan, the incidence rate of HNSCC in AA has been higher than for NAA, and the overall 5-year relative survival rate is lower for AA than NAA (36.2% vs. 47.6%). In this study, we found that the rate of loss of heterozygosity of chromosomal arms 1p, 3p, 4q, 9p, 13q, and 17p ranged from 68.8% to 83.3% for HNSCC in AA and from 66.7% to 90.0% in NAA. The difference in the rates of microsatellite alterations in chromosomal arms 3p, 4q, and 9p between AA and NAA were between 12.5% and 20% and were not statistically significant. CONCLUSION: The incidence and clinical outcomes for AA with HNSCC are different from that of NAA in southeast Michigan. In our group of patients with HNSCC, differences in rates of microsatellite alterations and survival were found between AA and NAA; however, these differences were not statistically significant. We conclude that genetic difference, as determined by the rates of microsatellite alterations, is not predictive of outcome difference between AA and NAA HNSCC patients.

Adult↗

The sensitivity of Medicare claims data for case ascertainment of six common cancers.

BACKGROUND: Although Medicare claims data have been used to identify cases of cancer in older Americans, there are few data about their relative sensitivity. OBJECTIVES: To investigate the sensitivity of diagnostic and procedural coding for case ascertainment of breast, colorectal, endometrial, lung, pancreatic, and prostate cancer. SUBJECTS: Three hundred and eighty nine thousand and two hundred and thirty-six patients diagnosed with cancer between 1984 and 1993 resided in one of nine Surveillance Epidemiology and End Results (SEER) areas. MEASURES: The sensitivity of inpatient and Part B diagnostic and cancer-specific procedural codes for case finding were compared with SEER. RESULTS: The sensitivity of inpatient and inpatient plus Part B claims for the corresponding cancer diagnosis was 77.4% and 91.2%, respectively. The sensitivity of inpatient claims alone was highest for colorectal (86.1%) and endometrial (84.1%) cancer and lowest for prostate cancer (63.6%). However, when Part B claims were included, the sensitivity for diagnosis of breast cancer was greater than for other cancers (93.6%). Inpatient claim sensitivity was highest for earlier years of the study, and, because of more complete data and longer follow up, the highest sensitivity of combined inpatient and Part B claims was achieved in the late 1980s or early 1990s. CONCLUSIONS: Medicare claims provide reasonably high sensitivity for the detection of cancer in the elderly, especially if inpatient and Part B claims are combined. Because the study did not measure other dimensions of accuracy, such as specificity and predictive value, the potential costs of including false positive cases need to be assessed.

Aged↗

Use of Medicare hospital and physician data to assess breast cancer incidence.

OBJECTIVES: Health claims data have the potential of being an inexpensive, timely, and nationally representative source of information about cancer. This study examined the utility of Medicare hospital and physician data as an independent source to identify incident breast cancer cases. METHODS: Data came from Medicare and the National Cancer Institute's SEER cancer registries. From 1992, for women residing in the SEER states (n = 659,260), Medicare hospital and physician claims were reviewed to identify women with a breast cancer diagnosis on a claim (n = 6,784). These women were matched with women in the SEER data who had been diagnosed with breast cancer in 1992 (n = 3,230). The sensitivity, specificity, and positive predictive value (PPV) of the Medicare data were calculated. Logistic regression models were used to identified cancer related procedures reported to Medicare that could distinguish true cases from false positive cases. Predicted values from these models were included to create plots of sensitivity versus false positive rates and sensitivity versus PPV. RESULTS: Medicare hospital data had 62% sensitivity, 99.9% specificity, and 88% PPV. Physician claims increased sensitivity by 14%, with specificity of 99.4%, and a PPV of 10%. Inclusion of additional cancer related diagnoses and procedures improved the ability to distinguish true cases from false positives, although the number of false positive cases remained high. CONCLUSIONS: The Medicare data overall offer limited potential to assess breast cancer incidence, largely because of low sensitivity and poor PPV. The Medicare data may have utility to identify women undergoing selected breast cancer treatments. In addition, the data may be used to help registries focus case-finding efforts, particularly for persons undergoing cancer related treatments.

Breast Neoplasms↗

The utility of Medicare claims data for measuring cancer stage.

BACKGROUND: The validity of using claims data for measuring tumor stage, one of the most important determinants of choice of therapy and long-term survival, is unknown. OBJECTIVES: To determine the relative accuracy of both inpatient and hospital Outpatient Medicare claims for measuring the stage of disease of six commonly diagnosed cancers. RESEARCH DESIGN: Analysis of a database linking Surveillance, Epidemiology, and End Results (SEER) registry data and Medicare claims in patients aged 65 years with cancer. SUBJECTS: Three hundred twenty thousand, six hundred and thirty seven cases of invasive breast, colorectal, endometrial, lung, pancreatic, and prostate cancers diagnosed between 1984 and 1993. MEASURES: Using SEER files as the "gold standard," concordance with Medicare claims, as well as sensitivity and positive predictive value of coding for each stage was measured. RESULTS: Although Medicare data correctly categorized local, regional, and distant stage tumors in 97%, 33%, and 65%, respectively, the data substantially overestimated the proportion of localized tumors and underestimated the rate of regional stage disease. The highest concordance was observed for breast and colorectal cancer. However, the sensitivity and positive predictive values were never simultaneously 80% within one stage of a specific cancer. The accuracy of coding for stage in Outpatient files was inferior to inpatient data. CONCLUSIONS: With few exceptions, Medicare claims have limited utility as a measure of cancer stage. If tumor registry data are not available, investigators should consider the trade offs in sensitivity and predictive value when considering a study that will use claims data.

Aged↗

Linked insurance-tumor registry database for health services research.

OBJECTIVE: Breast cancer screening and treatment data are often limited to restricted populations, including women older than 65 years old. The goal of this project was to develop procedures to link tumor registry and insurance claims databases on women younger than 65 years old with breast cancer and to assess the accuracy and validity of the linked dataset. METHODS: Iowa Cancer Registry (ICR) and Wellmark Blue Cross/Blue Shield of Iowa (BC/BS) membership files of women with incident in situ or invasive breast cancer from 1989 to 1996 were linked. An automated deterministic match was followed with visual inspection from three independent reviewers applying a matching protocol. Matched and overall registry data were compared to assess population representativeness. Claims from BC/BS for incident cases during 1994 were examined for coding of a recent breast cancer diagnosis or treatment. RESULTS: The final dataset included 4,397 matched cases of patients aged 21 years and older from 1989 to 1996. The sociodemographic and tumor characteristics of the ICR population younger than 65 years old (n = 7,469) with breast cancer or carcinoma in situ were nearly identical with those of the matched patients younger than 65 years old (n = 3,449). Nearly all (96%) of the 445 matched incident cases in 1994 had claims data (CPT, DRG, or ICD-9 code) indicative of breast cancer. Treatment patterns varied by data source, with agreement ranging from 76% to 82%. CONCLUSIONS: The validity and generalizability of these data demonstrate their potential for further health services research among younger insured women with breast cancer. Additionally, the process outlined may be useful for developing other datasets to study other cancers in the population younger than 65 years old.

Adult↗

Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer.

OBJECTIVES: This study develops estimates of long-term, cancer-related treatment cost using a modeling approach and data from the SEER-Medicare linked database. The method is demonstrated for colorectal cancer. METHODS: Data on Medicare payments were obtained for colorectal cancer patients for the years 1990 to 1994 from the SEER-Medicare linked database. Claims payment data for control subjects were obtained for Medicare enrollees without cancer residing in the same areas as patients. Estimates of long-term cost (< or = 25 years following the date of diagnosis) were obtained by combining treatment/phase-specific cost estimates with estimates of long-term survival from SEER. Treatment phases were defined as initial care, terminal care, and continuing care. Cancer-related estimates for each phase were obtained by subtracting costs for control subjects from the observed costs for cancer patients, matching on age group, gender, and registry area. Estimates of long-term cost < or = 11 years obtained by this method were compared with 11-year estimates obtained by application of the Kaplan-Meier sample average (KMSA) method. RESULTS: The mean initial-phase cancer-related cost was approximately $18,000 but was higher among patients with more advanced cancer. The mean continuing-phase cancer-related cost was $1,500 per year and declined with increasing age, but was higher on an annual basis among persons with later stages of cancer and shorter survival time. The mean terminal-phase cancer-related cost was $15,000 and declined with both age at death and more advanced stage at diagnosis. After the phase-specific estimates were combined, the average long-term cancer-related cost was $33,700 ($31,300 at 3% discount rate) for colon cancer compared with $36,500 ($33,800 at 3% discount rate) for cancer of the rectum. This represented about half of the total long-term cost for Medicare enrollees diagnosed with this disease. Long-term cost was highest for Stage III cancer and lowest for in situ cancer. Eleven-year cancer-related costs estimated by the KMSA method were similar to estimates using the phase-based approach. CONCLUSIONS: This paper demonstrates that valid estimates of cancer-related long-term cost can be obtained from administrative claims data linked to incidence cancer registry data.

Age Distribution↗

Underutilization of mammography in older breast cancer survivors.

BACKGROUND: Annual mammography is recommended for all breast cancer survivors. OBJECTIVES: To elucidate mammography use among older survivors of breast cancer and to explore determinants of such use. RESEARCH DESIGN: Retrospective cohort study using data from the Surveillance, Epidemiology, and End Results (SEER) registry linked to Medicare claims. SUBJECTS: A cohort of 3885 breast cancer survivors aged > or =65 years diagnosed with early-stage breast cancer in the United States in 1991. MEASURES: Medicare mammogram claims during the 2-year period following initial breast cancer treatment. RESULTS: Overall, 62% of the cohort underwent annual mammography, 23% underwent mammography in 1 of 2 years, and 15% had no mammography claim in the 2 years evaluated. Twenty-two percent of the women who underwent breast-conserving surgery (BCS) without radiotherapy had no mammogram in the 2-year period evaluated, compared with 17% of those who underwent mastectomy and 4% of those who underwent BCS with radiotherapy. In multivariate analyses controlling for age, cancer stage, and other patient factors, the use of annual mammography was significantly lower among women treated with mastectomy or BCS without radiotherapy than among women treated with BCS with radiotherapy. CONCLUSIONS: Mammography is underused in the follow-up care of older breast cancer survivors. Underuse is of particular concern in women treated with BCS without radiotherapy because of the high risk of local disease recurrence. It is unknown whether poorer follow-up care contributes to the previously described lower rate of long-term survival among women who received this therapy.

Aged↗

Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment.

BACKGROUND: Although health claims data are increasingly used in evaluating variations in patterns of cancer care and outcomes, little is known about the comparability of these data with tumor registry information. OBJECTIVES: To evaluate the agreement between Medicare claims and tumor registry data in measuring patterns of diagnostic and therapeutic procedures for older cancer patients. RESEARCH DESIGN: Analysis of a database linking Surveillance, Epidemiology and End Results (SEER) registry data and Medicare claims in patients aged > or =65 years with cancer. SUBJECTS: 361,255 Medicare patients with invasive breast, colorectal, endometrial, lung, pancreatic, and prostate cancer diagnosed between 1984 and 1993. MEASURES: Concordance of SEER files with corresponding Medicare claims. RESULTS: Medicare claims generally identified patients who underwent resection and radical surgery according to SEER (ie, concordance > or =85%-90%) but less likely biopsy or local excision (ie, concordance < or =50%). In some instances, claims also categorized patients as having more invasive surgery than was listed in SEER and also provided incremental information about the use of surgical treatment after 4 months. SEER files and, to a lesser degree, Medicare claims identified radiation therapy not included in the other data source, and Medicare files also captured a significant number of patients with codes for chemotherapy. CONCLUSIONS: Medicare files may be appropriate for studies of patterns of use of surgical treatment, but not for diagnostic procedures. The potential benefit of Medicare claims in identifying delayed surgical intervention and chemotherapy deserves further study.

Aged↗

Accuracy and completeness of Medicare claims data for surgical treatment of breast cancer.

BACKGROUND: Although a number of studies have used Medicare claims data to study trends and variations in breast cancer treatment, the accuracy and completeness of information on surgical treatment for breast cancer in the Medicare data have not been validated. OBJECTIVES: This study assessed the accuracy and completeness of Medicare claims data for breast cancer surgery to determine whether Medicare claims can serve as a source of data to augment information collected by cancer registries. METHODS: We used the Surveillance, Epidemiology and End Results (SEER) Cancer Registry-Medicare data and compared Medicare claims on surgery with the surgery recorded by the SEER registries for 23,709 women diagnosed with breast cancer at > or =65 years of age from 1991 through 1993. RESULTS: More than 95% of women having mastectomies according to the Medicare data were confirmed by SEER. For breast-conserving surgery, 91% of cases were confirmed by SEER. The Medicare physician services claims and inpatient claims were approximately equal in accuracy on type of surgery. The Medicare outpatient claims were less accurate for breast-conserving surgery. In terms of completeness, when the 3 claims sources were combined, 94% of patients receiving breast cancer surgery according to SEER were identified by Medicare. CONCLUSIONS: The combined Medicare claims database, which includes the inpatient, outpatient, and physician service claims, provides valid information on surgical treatment among women known to have breast cancer. The claims are a rich source of data to augment the information collected by tumor registries and provide information that can be used to follow long-term outcomes of Medicare beneficiaries.

Breast Neoplasms↗

Validation study of retrospective recall of disease-targeted function: results from the prostate cancer outcomes study.

OBJECTIVES: This was an ancillary methodological study within the Prostate Cancer Outcomes Study (PCOS) to assess the validity of 6-month retrospective recall of prediagnostic disease-targeted function among men diagnosed with prostate cancer. METHODS: A convenience sample of 133 prostate cancer cases were administered a baseline questionnaire shortly after diagnosis that asked about prediagnostic urinary, sexual, and bowel function. They were surveyed again concerning the same items 6 months later and asked to recall their prediagnostic function. Reports of prediagnostic function obtained at baseline and 6 months are compared, as are measures of change derived from these reports. Percent agreement and weighted kappas are calculated to measure the extent of agreement. RESULTS: Over 70% of the men reported prediagnostic functioning at the highest level on 12 of 17 survey items. For each of these items, recall at 6 months was identical to the baseline survey response for > or =69% of the men. The values of the weighted kappas for changes computed with baseline reports (prospective) and changes computed with 6-month recall (retrospective) ranged from 0.396 to 0.919 for the 17 individual items. Intraclass correlations for the retrospective versus prospective changes in the multi-item function scores were 0.828 for urinary, 0.618 for bowel, and 0.692 for sexual function. CONCLUSIONS: At baseline, men recently diagnosed with prostate cancer report few disease-related problems before diagnosis, and a high percentage of men recall this accurately 6 months later. There is reasonably high agreement between baseline and 6-month estimates of prediagnostic function and between prospective and retrospective measures of change over 6 months.

Aged↗